(NASDAQ: BFRI) Biofrontera's forecast annual revenue growth rate of 15.65% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Biofrontera's revenue in 2026 is $41,705,000.On average, 4 Wall Street analysts forecast BFRI's revenue for 2026 to be $555,543,469, with the lowest BFRI revenue forecast at $528,531,008, and the highest BFRI revenue forecast at $577,477,261. On average, 3 Wall Street analysts forecast BFRI's revenue for 2027 to be $649,871,588, with the lowest BFRI revenue forecast at $624,385,058, and the highest BFRI revenue forecast at $668,986,487.
In 2028, BFRI is forecast to generate $752,842,764 in revenue, with the lowest revenue forecast at $723,325,913 and the highest revenue forecast at $774,986,226.